| Citation: |
SUN Wei, DAI Hong. Clinical efficacy and safety of programmed death 1 inhibitors combined with anlotinib as the second-line therapy in treating patients with advanced esophageal squamous cell carcinoma[J]. Journal of Clinical Medicine in Practice, 2023, 27(19): 17-21. DOI: 10.7619/jcmp.20231808
|
To analyze the clinical efficacy and safety of programmed death 1 (PD-1) inhibitors combined with anlotinib as the second-line therapy in treating patients with advanced esophageal squamous cell carcinoma.
A total of 68 patients with advanced esophageal squamous cell carcinoma diagnosed by histopathology from January 2021 to June 2022 were selected, and they were treated with PD-1 inhibitors plus arotinib targeted therapy after failure of first-line platinum containing chemotherapy regimen, including 32 cases with camrelizumab, 20 cases with sintilimab, and 16 cases with treprinumab immunotherapy. The clinical efficacy and safety of three groups were analyzed.
After efficacy evaluation for 68 patients, there were 18 cases of partial remission, 40 cases of stable disease, and 10 cases of disease progression. The objective response rate and disease control rate were 26.5% and 85.3% respectively, the median progression free survival was 7.5 months (95%CI, 6.6 to 8.4), and the median overall survival was not achieved. In terms of safety, the most adverse reactions were at grade 1 and 2, the incidence of adverse reactions at grade 3 was 14.7%, and adverse reactions at grade 4 and 5 were not observed; all the adverse reactions alleviated after performing targeted treatment.
Patients with advanced esophageal squamous cell carcinoma can significantly benefit from the combination of PD-1 inhibitors and anlotinib as the second-line therapy, and the adverse reactions are controllable.
| [1] |
SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. doi: 10.3322/caac.21660
|
| [2] |
SUN J M, SHEN L, SHAH M A, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study[J]. Lancet, 2021, 398(10302): 759-771. doi: 10.1016/S0140-6736(21)01234-4
|
| [3] |
DOKI Y, AJANI J A, KATO K, et al. Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma[J]. N Engl J Med, 2022, 386(5): 449-462. doi: 10.1056/NEJMoa2111380
|
| [4] |
LUO H Y, LU J, BAI Y X, et al. Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st randomized clinical trial[J]. JAMA, 2021, 326(10): 916-925. doi: 10.1001/jama.2021.12836
|
| [5] |
WANG Z X, CUI C X, YAO J, et al. Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): a multi-center phase 3 trial[J]. Cancer Cell, 2022, 40(3): 277-288, e3. doi: 10.1016/j.ccell.2022.02.007
|
| [6] |
LU Z H, WANG J Y, SHU Y Q, et al. Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial[J]. BMJ, 2022, 377: e068714.
|
| [7] |
CHAMBERS A, KUNDRANDA M, RAO S, et al. Anti-angiogenesis revisited: combination with immunotherapy in solid tumors[J]. Curr Oncol Rep, 2021, 23(9): 100. doi: 10.1007/s11912-021-01099-7
|
| [8] |
MENG X R, WU T, HONG Y G, et al. Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial[J]. Lancet Gastroenterol Hepatol, 2022, 7(3): 245-253. doi: 10.1016/S2468-1253(21)00378-2
|
| [9] |
XU Q, CHEN C B, SUN Y, et al. A phase Ⅱ study of sintilimab plus anlotinib for Chinese patients (pts) with persistent, recurrent or metastatic cervical cancer (CC)[J]. Gynecol Oncol, 2021, 162: S78.
|
| [10] |
JIN S L, ZHAO R H, ZHOU C, et al. Feasibility and tolerability of sintilimab plus anlotinib as the second-line therapy for patients with advanced biliary tract cancers: an open-label, single-arm, phase Ⅱ clinical trial[J]. Int J Cancer, 2023, 152(8): 1648-1658. doi: 10.1002/ijc.34372
|
| [11] |
刘良忠, 李小红, 张军, 等. 安罗替尼后线治疗抗PD-1免疫治疗失败的晚期食管鳞癌的临床疗效观察[J]. 重庆医学, 2022, 51(2): 276-280. https://www.cnki.com.cn/Article/CJFDTOTAL-CQYX202202021.htm
|
| [12] |
HUANG J, XIAO J X, FANG W T, et al. Anlotinib for previously treated advanced or metastatic esophageal squamous cell carcinoma: a double-blind randomized phase 2 trial[J]. Cancer Med, 2021, 10(5): 1681-1689. doi: 10.1002/cam4.3771
|
| [13] |
孙魏, 邹玺, 张微, 等. 安罗替尼联合替吉奥二线治疗复发转移性食管鳞癌的临床疗效[J]. 南方医科大学学报, 2021, 41(2): 250-255. https://www.cnki.com.cn/Article/CJFDTOTAL-DYJD202102014.htm
|
| [14] |
HUANG J, XU J M, CHEN Y, et al. Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study[J]. Lancet Oncol, 2020, 21(6): 832-842. doi: 10.1016/S1470-2045(20)30110-8
|
| [15] |
VAN CUTSEM E, KATO K, AJANI J, et al. Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC, RATIONALE 302): impact on health-related quality of life (HRQoL)[J]. Journal of Clinical Oncology, 2021, 39(15_suppl): 4012-4012 doi: 10.1200/JCO.2021.39.15_suppl.4012
|
| [16] |
KOJIMA T, SHAH M A, MURO K, et al. Randomized phase Ⅲ KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer[J]. J Clin Oncol, 2020, 38(35): 4138-4148. doi: 10.1200/JCO.20.01888
|
| [17] |
OKADA M, KATO K, CHO B C, et al. Three-year follow-up and response-survival relationship of nivolumab in previously treated patients with advanced esophageal squamous cell carcinoma (ATTRACTION-3)[J]. Clin Cancer Res, 2022, 28(15): 3277-3286. doi: 10.1158/1078-0432.CCR-21-0985
|
| [18] |
葛青青, 石变, 高启龙, 等. PD-1抑制剂联合安罗替尼治疗化疗后进展的晚期食管鳞状细胞癌的回顾性研究[J]. 中国肿瘤临床, 2022, 49(10): 519-523. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGZL202210008.htm
|
© 2020 《实用临床医药杂志》编辑部
Address: 江苏省扬州市江阳中路136号，扬州大学江阳路北校区14号楼201室China Pos: 225009Tel: 0514-87978917、87978989、87978807
Supported by:
Beijing Renhe Information Technology Co., Ltd.
苏公网安备 32100302010246号
DownLoad: